Blog

Home  /  EUnetHTA Joint Action 3 (2016-2021)   /  PTJA12 – Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.

PTJA12 – Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.

The final project plan of the relative effectiveness assessment of ‘Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy’ is now available for access.

The final assessment report will be published on July 30th, 2020.

PTJA12 Final Project Plan